Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Celebrex approved by FDA for adjunctive therapy of FAP

Dec. 27, 1999

FDA gives the go-ahead to PhotoCure for phase I testing of Metvix

Dec. 27, 1999

Chemoprevention study will evaluate fenretinide in women at risk of ovarian cancer

Dec. 27, 1999

Aronex to submit NDA amendment for Atragen in first half of 2000

Dec. 23, 1999

DA-125: well tolerated but not effective in phase II trial in NSCLC

Dec. 23, 1999

Spanish investigators disclose new diazaanthraquinones for malignant tumors

Dec. 23, 1999

Cytoclonal describes recent progress in telomerase production, inhibitors

Dec. 23, 1999

Targretin overcomes tamoxifen resistance in preclinical testing

Dec. 23, 1999

New FTase inhibitors from Schering-Plough with good cellular activity

Dec. 22, 1999

Cytotoxic polyheterocyclic compounds designed at Taiwan research institute

Dec. 22, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...